Meeting of the CDER Antiviral Drugs Advisory Committee

March 11, 2005

CONSULTANTS AND GUESTS

Special Government Employee (SGE) Consultants (voting)

Samuel K. So, M.B., B.S.

Professor of Surgery

Stanford University

300 Pasteur Drive H3680

Stanford, California 94305

Kathleen Schwarz, M.D.

Professor of Pediatrics

Johns Hopkins University School of Medicine

600 North Wolfe Street, Brady 320

Baltimore, Maryland 21287

Government Employee Consultants (voting)

Beth P. Bell, M.D., M.P.H.

Chief, Epidemiology Branch

Division of Viral Hepatitis

National Center for Infectious Diseases

Centers for Disease Control and Prevention

1600 Clifton Road, NE

Atlanta, Georgia 30333

Ronald Herbert, D.V.M, Ph.D.

Veterinary Medical Officer

National Institutes of Health

National Institute of Environmental Health Sciences

111 Alexander Drive, Building 101, MD B3-08

Research Triangle Park, North Carolina 27709

Leonard B. Seeff, M.D.

Senior Scientist for Hepatitis Research

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases

31A Center Drive, Room 9A27

Bethesda, Maryland 20817

SGE Patient Representative (voting)

Brett Grodeck, Santa Monica, California

FDA Participants at the Table (non-voting)

Mark J. Goldberger, M.D., M.P.H.

Director, Office of Drug Evaluation IV, CDER

Debra B. Birnkrant, M.D.

Director, Division of Antiviral Drug Products, CDER

Katherine A. Laessig, M.D.

Medical Team Leader, Division of Antiviral Drug Products, CDER

Linda L. Lewis, M.D.

Medical Officer, Division of Antiviral Drug Products, CDER

James G. Farrelly, Ph.D.

Pharmacology/Toxicology Team Leader, Division of Antiviral Drug Products, CDER